SOURCE: Revolutions Medical Corp.

Revolutions Medical Corp.

September 02, 2009 12:46 ET

Competitor Paves Way for Broad Adoption of Revolutions Medical's Rev Vac Safety Syringe

MOUNT PLEASANT, SC--(Marketwire - September 2, 2009) - Revolutions Medical Corporation ("Revolutions Medical" or the "Company") (OTCBB: RMCP), producers of the Rev Vac safety syringe, today confirmed that the opportunities for its Rev Vac safety syringe became even more significant with the August 31 announcement of close competitor Retractable Technologies, Inc. ("Retractable Technologies"). Per the announcement, Retractable Technologies has been awarded a contract by the Department of Health and Human Services to supply a portion of the safety engineered syringes to be used in the United States' efforts to vaccinate the U.S. population against the H1N1 virus (swine flu).

"It is not often that a competitor's achievements are cause for excitement, but this is that rare case," stated Revolutions Medical CEO Ron Wheet. "Retractable Technologies has proven that major regulatory bodies are actively seeking and engaging suppliers of safety syringes, for efforts on a massive scale. Retractable Technologies' VanishPoint safety needle is indeed a quality product, but one against which we believe our Rev Vac safety syringe compares very favorably. Both have similar features, but the VanishPoint product relies on an additive metal spring that injects some uncertainty of performance, while our Rev Vac requires no additional parts and operates through a consistently reliable vacuum mechanism. Our vacuum is created by design when the plunger is drawn, ensuring predictable speed and ease of retraction."

Added Revolutions Medical President Tom O'Brien, "And likely as important to cost-sensitive agencies and hospitals, we will bring the Rev Vac to market at less than half the published cost of the VanishPoint safety needle. Cost is a function of design, parts count and manufacturing investment; the financial commitment we have made to engineering a patented design of such elegant simplicity allows us to outperform competitive products, while keeping production costs lower than our peers.

"This announcement confirms the magnitude of the opportunity before us, and we believe our product's competitive advantages will well position Revolutions Medical to pursue and win business of this kind."

Revolutions Medical is currently finalizing Rev Vac safety syringe production schedules, gearing up global distribution, and having discussions with potential corporate partners worldwide.

To be added to the Revolutions Medical investor email list, please email with RMCP in the subject line.

About Revolutions Medical Corporation (

Revolution Medical's products include the Rev Vac safety syringe (FDA Approved), safety blood drawing device and safety IV catheter. Revolutions Medical also provides software solutions and proprietary tools that are compatible with standard MRIs and standard PACS. The software includes sorting of images, color, 3D and automatic segmentation of images.


The information contained herein includes forward-looking statements. These statements relate to future events or to our future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance, or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond our control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects our current views with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to our operations, results of operations, growth strategy and liquidity. We assume no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. The safe harbor for forward-looking statements contained in the Securities Litigation Reform Act of 1995 protects companies from liability for their forward-looking statements if they comply with the requirements of the Act.

Contact Information